Gene therapy for the treatment of heart failure: promise postponed
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Gene therapy has emerged as a powerful tool in targeting the molecular mechanisms implicated in heart failure. Refinements in vector technology, including the development of recombinant adeno-associated vectors, have allowed for safe, long-term, and efficient gene transfer to the myocardium. These advancements, coupled with evolving delivery techniques, have placed gene therapy as a viable therapeutic option for patients with heart failure. However, after much promise in early-phase clinical trials, the more recent larger clinical trials have shown disappointing results, thus forcing the field to re-evaluate current vectors, delivery systems, targets, and endpoints. We provide here an updated review of current cardiac gene therapy programmes that have been or are being translated into clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Follow-up analysis of available patient cardiac tissue revealed transduction efficiency far below doses that were effective in preclinical models, which likely explained the neutral outcome.63”
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Epidemiology and risk profile of heart failure
Bui, A. L., Horwich, T. B., & Fonarow, G. C. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.165 · Cited by 2,077 · cited 2×
“Heart Failure (HF) remains a leading cause of mortality (≈50% after 5 years) and hospitalizations throughout the world.(1) It is estimated that over 23 million people worldwide are afflicted with HF and its prevalence will continue to grow in the next 10 years with the ageing of the population.”
BackgroundAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure.
Gwathmey, J. K., Copelas, L., MacKinnon, R., Schoen, F. J., Feldman, M. D., Grossman, W., & Morgan, J. P. (1987) · Circulation Research · doi:10.1161/01.res.61.1.70 · Cited by 924
Jessup, M., Greenberg, B., Mancini, D., Cappola, T., Pauly, D. F., Jaski, B., Yaroshinsky, A., Zsebo, K. M., Dittrich, H., & Hajjar, R. J. (2011) · Circulation · doi:10.1161/circulationaha.111.022889 · Cited by 760
Self-citationZangi, L., Lui, K. O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. M., Später, D., Xu, H., Tabebordbar, M., Gorbatov, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2682 · Cited by 646
Progress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
Greenberg, B., Butler, J., Felker, G. M., Ponikowski, P., Voors, A. A., Desai, A. S., Barnard, D., Bouchard, A., Jaski, B., Lyon, A. R., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00082-9 · Cited by 525 · cited 4×
“0 × 10(13) DRP in improving clinical outcomes of patients with advanced HF.(34) Two other clinical trials with AAV1.”
BackgroundMethodResultInfluential
Cited by
Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives
Poller, W., Dimmeler, S., Heymans, S., Zeller, T., Haas, J., Karakas, M., Leistner, D.-M., Jakob, P., Nakagawa, S., Blankenberg, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx165 · Cited by 408
Self-citationMesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges
Bagno, L., Hatzistergos, K. E., Balkan, W., & Hare, J. M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.009 · Cited by 337
Gene therapy: Comprehensive overview and therapeutic applications
Sayed, N., Allawadhi, P., Khurana, A., Singh, V., Navik, U., Pasumarthi, S. K., Khurana, I., Banothu, A. K., Weiskirchen, R., & Bharani, K. K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120375 · Cited by 337
Calcium Signaling and Transcriptional Regulation in Cardiomyocytes
Dewenter, M., von der Lieth, A., Katus, H. A., & Backs, J. (2017) · Circulation Research · doi:10.1161/circresaha.117.310355 · Cited by 248
SERCA control of cell death and survival
Chemaly, E. R., Troncone, L., & Lebeche, D. (2018) · Cell Calcium · doi:10.1016/j.ceca.2017.07.001 · Cited by 233
Metadata
- Authors
- Hulot, J.-S., Ishikawa, K., & Hajjar, R. J.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Hajjar, Roger J.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-02-27
- Volume
- 37
- Issue
- 21
- Pages
- 1651-1658
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC4887702
- OpenAlex
- W2290678689
- Cited by
- 150
- References
- 36
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 11 · 2023: 12 · 2022: 13 · 2021: 11 · 2020: 10 · 2019: 24 · 2018: 17 · 2017: 19 · 2016: 8
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- public-domain
- Locations
- European Heart Journal (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Institutes of Health (R01 HL117505, HL119046, HL128072, HL129814, P50 HL112324, T32HL007824, R01 HL113497)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- gene therapy, heart failure, adeno-associated virus vectors, clinical trials, translational research, cardiac vector, therapeutic target
- MeSH terms
- Animals, Calcium, Clinical Trials as Topic, Genetic Vectors, Heart Failure, Humans, Myocardial Contraction, Stem Cells, Calcium Channels, Genetic Therapy, Gene Transfer Techniques, Vascular Endothelial Growth Factor A, Angiogenesis Inducing Agents, Mice, Sarcoplasmic Reticulum Calcium-Transporting ATPases, Chemokine CXCL12
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene therapy for the treatment of heart failure: promise postponed. https://app.cochat.ai/papers/10.1093/eurheartj/ehw019
- The paper
- Hulot, J.-S., Ishikawa, K., & Hajjar, R. J. (2016). Gene therapy for the treatment of heart failure: promise postponed. European Heart Journal. https://doi.org/10.1093/eurheartj/ehw019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.